ScreenerHero
NBPNovaBridge Biosciences
NAS · US · Healthcare · Biotechnology · novabridge.com
1.910USDMkt Cap: 220.89M $P/E: —

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap220.89M $
Enterprise Value21.21M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.27M $
Revenue/Share—
Last Price1.910 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees30
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.80
PEG—
EV/EBITDA-0.23
EV/Revenue—
P/S—
P/B0.95
EPS (TTM)-0.48
EPS (Forward)-1.06
52W Range
1.78068% of range1.970
52W High1.970 USD
52W Low1.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.03%
ROA-17.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.60M $
CapEx (TTM)7.00K $
FCF Margin—
FCF Yield-16.80%
Net Debt-207.78M $
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity0.01
Current Ratio8.09
Quick Ratio7.91
Book Value/Sh2.002 USD
Cash/Share1.823 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)8.000 USD
Upside (mean)+318.8%
Target Range7.000 USD – 9.000 USD
$7.000+318.8% to mean$9.000
# Analysts3
Ownership
Shares Out.115.65M
Float64.21M
Insiders14.41%
Institutions35.02%
Short Interest
Short Ratio9.2d
Short % Float6.53%
Short % Out.3.91%
Shares Short4.52M
Short (prev mo.)3.47M
Technical
SMA 501.755 (+8.8%)
SMA 2002.846 (-32.9%)
Beta1.48
S&P 52W Chg21.00%
Avg Vol (30d)383.94K
Avg Vol (10d)248.92K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—